Platinum resistance in breast and ovarian cancer cell lines.

  • Eckstein N
  • 106

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Breast and ovarian cancers are among the 10 leading cancer types in females with mortalities of 15% and 6%, respectively. Despite tremendous efforts to conquer malignant diseases, the war on cancer declared by Richard Nixon four decades ago seems to be lost. Approximately 21,800 women in the US will be diagnosed with ovarian cancer in 2011. Therefore, its incidence is relatively low compared to breast cancer with 207.090 prognosed cases in 2011. However, overall survival unmasks ovarian cancer as the most deadly gynecological neoplasia. Platinum-based chemotherapy is emerging as an upcoming treatment modality especially in triple negative breast cancer. However, in ovarian cancer Platinum-complexes for a long time are established as first line treatment. Emergence of a resistant phenotype is a major hurdle in curative cancer therapy approaches and many scientists around the world are focussing on this issue. This review covers new findings in this field during the past decade.

Author-supplied keywords

  • Animals
  • Antineoplastic Agents
  • Antineoplastic Agents: therapeutic use
  • Breast Neoplasms
  • Breast Neoplasms: drug therapy
  • Drug Resistance
  • Female
  • Humans
  • Neoplasm
  • Neoplasm: drug effects
  • Organoplatinum Compounds
  • Organoplatinum Compounds: adverse effects
  • Ovarian Neoplasms
  • Ovarian Neoplasms: drug therapy
  • Prognosis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Niels Eckstein

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free